trending Market Intelligence /marketintelligence/en/news-insights/trending/mbwvrfopulz8vsaf7mjxbg2 content esgSubNav
In This List

Sanofi secures antitrust clearance for $11.6B acquisition of Bioverativ

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Sanofi secures antitrust clearance for $11.6B acquisition of Bioverativ

French drugmaker Sanofi secured U.S. antitrust clearance for its $11.6 billion acquisition of Waltham, Mass.-based hemophilia specialist Bioverativ Inc.

The waiting period under the Hart-Scott-Rodino Act related to the deal has expired, which means the transaction has received antitrust clearance.

The acquisition is still subject to other conditions, including the tender of at least a majority of Bioverativ's common stock.

On Feb. 7, Sanofi started a tender offer to buy all of Bioverativ's outstanding shares for $105 apiece in cash. The offer will expire March 7.